• Testosterone therapy can improve libido in postmenopausal women.
• Sexual dysfunction in women is complex and multifactorial.
• Low sexual desire is only considered a disorder if it causes distress.
• Psychosocial factors play a significant role in sexual health.
• Testosterone levels do not change significantly at menopause.
• The placebo effect can significantly influence treatment outcomes.
• Individualized care is crucial in managing sexual dysfunction.
• Dosing for testosterone therapy should be carefully monitored.
• Current medications for low libido have modest benefits.
• Evidence for testosterone therapy in premenopausal women is still emerging.
  
  Tap to Follow Dr.Susan

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Show Notes:
In this episode of Docs Who Lift, the Nadolsky brothers welcome back Dr. Sean Wharton, clinical trialist and one of the leading researchers behind the next generation of oral GLP-1 medications. Together, they break down:

The OASIS-4 trial results on 25mg oral semaglutide and how it stacks up to injectable Wegovy

How orforglipron, Eli Lilly’s new small-molecule GLP-1, differs from peptide-based drugs

Why these new therapies could make weight management more accessible and affordable

The fascinating pharmacology behind “snack molecules” and small-molecule receptor agonists

Common misconceptions about bioavailability, dosing, and side effects

The potential role of oral GLP-1s for patients with mild obesity or cardiometabolic disease

Whether you’re a clinician, researcher, or patient curious about the future of obesity medicine, this conversation offers a clear look at how science is shifting toward needle-free solutions.

Oasis 1 Trial Link

Oasis 4 Trial Link

Attain 1 Trial Link

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Docs Who Lift, the Nadolsky brothers dive deep into the newly released American Association of Clinical Endocrinology (ACE) Algorithm for Obesity Care led by Dr. Karl himself. They explore:

Why ACE moved away from a BMI-only approach to a person-centered, complication-centric model

The new staging framework (ABCD) that helps individualize treatment intensity

How to interpret “clinical” vs “preclinical” obesity under the new model

Updated targets for clinically meaningful weight loss (5%, 10%, 15% tiers)

The emphasis on resistance training, sleep, and behavioral health alongside nutrition

Practical guidance for selecting anti-obesity medications and identifying the right therapy for each patient

Whether you’re a clinician, health professional, or patient trying to understand modern obesity care, this episode breaks it all down in a practical, real-world way without the jargon.

Youtube Video to follow along the graphic mentioned

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.